INTRODUCTION
Melanoma is a complex disease that arises through multiple etiologic pathways. Studies of the genetic and molecular characteristics of melanomas are valuable in the development of new treatment strategies. Mutations in the p16 cyclin-dependent kinase inhibitor 2A (p16CDKN2A) gene, located on chromosome 9p21, are the most recognized cause of inherited melanoma susceptibility, 1, 2 contributing to geographic variations in incidence. In Italy, there is a gradient of melanoma incidence-higher in northern regions and lower in southern regions; such a gradient has been analogously described for the p16CDKN2A mutation prevalence.
3,4
The MAPK-ERK pathway, which includes the cascade of BRAF, NRAS, MEK1/2, and ERK1/2 gene products, also plays a major role in the development and progression of melanoma. 5, 6 Mutations of BRAF and NRAS genes have been identified with high frequency in nevi and cutaneous melanomas, suggesting that they represent early events in the development of melanocytic tumors.
7-9 Furthermore, melanomas on skin that have not been chronically exposed to sun usually carry either a mutated BRAF or a mutated NRAS (somatic mutations in such genes are mutually exclusive).
8,10-12
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Similar rates of BRAF mutations are present in primary and metastatic melanomas, as well as in cultured malignant melanoma cell lines, suggesting that BRAF mutations occur before tumor dissemination and that their incidence remains constant during tumor progression. 6 However, prevalence of such mutations during the disease progression phases and among different types of metastasis remains inconclusive. The aim of this study was to investigate the prevalence and distribution of pathogenetic mutations in BRAF, NRAS, and p16CDKN2A genes among primary and metastatic melanoma tissues.
PATIENTS AND METHODS
Patients
Eligible patients had a histologically proven diagnosis of advanced melanoma (disease stages III and IV, according to American Joint Committee on Cancer [AJCC] guidelines) 13 and had primary and metastatic tumor tissue samples available for molecular analysis. Patients were enrolled consecutively between June 2008 and December 2010 from centers in Italy. To avoid bias, patients were included regardless of age of onset, family history of cancer, and disease characteristics. About one tenth of the present cohort (12 patients) had been tested for BRAF/NRAS/p16CDKN2A somatic mutations previously. 4 Patients were informed about the study aims and limits, and they provided written consent for the molecular analysis of their tissue samples. The study was reviewed and approved by the ethical review boards at both participating centers.
Samples
Paired samples of primary melanomas and synchronous or asynchronous metastases from the same patient were collected. Formalin-fixed, paraffin-embedded (FFPE) tumor tissues were taken from pathologic archives. By using light microscopy, the neoplastic portion of each tissue section was isolated to obtain tumor samples with at least 80% neoplastic cells (improving the sensitivity of nucleotide sequencing, which may detect a mutation when the mutant alleles are at least 15% to 20% of the analyzed DNA sample). Histologic classification, including Breslow thickness and disease stage at diagnosis, was confirmed by medical records, pathology reports, and/or review of pathologic material.
For reference, 29 melanoma cell lines cultured from primary and metastatic excised tumors were obtained from Istituto Dermopatico dell'Immacolata of Rome, the National Cancer Institute of Naples, and the publicly available American Type Culture Collection (ATCC). The cell line controls were obtained from primary tumors (n ϭ 6), lymph node metastases (n ϭ 7), subcutaneous metastases (n ϭ 9), visceral metastases (n ϭ 2), and the ATCC catalog (n ϭ 5). These cell lines were established as primary cell cultures from tumor samples from donor patients with documented diagnosis of melanoma, after informed consent.
Tissue sections of brain metastases were obtained from 24 patients surgically treated in other Italian clinical centers (after informed consent). An additional cohort of patients with brain metastasis was included to better assess the distribution of BRAF/NRAS mutations in such secondary tumors.
Mutation Analysis
Genomic DNA was isolated from tumor tissues or melanoma cell lines.
14 For paraffin-embedded samples, paraffin was removed by xylene treatment (Pisano et al 14 ) , and DNA was purified by using the QIAamp DNA FFPE tissue kit (QIAGEN, Valencia, CA). Polymerase chain reaction (PCR) was performed on 25 to 50 ng of isolated genomic DNA in a 9700 thermal cycler (Applied Biosystems, Foster City, CA); all PCRamplified products were directly sequenced by using an automated fluorescent cycle sequencer (ABI PRISM 3130, Applied Biosystems), as previously described. 4 Sequencing analysis was conducted in duplicate-starting from two different tumor sections and performing two different PCR-based amplifications-and in both directions (forward and reverse) for all samples. For discordant tumors, the sequence analysis was performed in triplicate-three different tumor sections and three different PCR-based amplifications-to avoid any chance of PCR artifacts. A nucleotide sequence was considered as valid when the quality value was higher than 20 (Ͻ 1/100 error probability); in this study, the quality value average was 35 (range, 30 to 45; Ͻ 1/1,000 to 1/10,000 error probability).
Mutation screening was conducted to analyze the full coding sequences and splice junctions of p16CDKN2A (exons 1␣, 2, and 3) and NRAS (exons 2 and 3) genes, and the entire sequence of the BRAF exons 11 and 15 (because almost all pathogenetic mutations of BRAF have been detected at either the kinase domain at exon 15 or the adenosine triphosphate-binding pocket at exon 11). 5, 6 Primer sets and PCR assay protocols were as previously described. 4 To confirm that each CDKN2A gene variant detected by sequencing was a real mutation or a polymorphism, 105 unrelated healthy individuals (corresponding to 210 control chromosomes), originating from the same geographic area and with no family history of cancer, were used as controls and screened for candidate sequence variations.
Statistical Analysis
Univariate analysis of the presence of BRAF, NRAS, or p16CDKN2A mutations versus the number and type of metastatic sites and primary melanoma locations was performed by using Pearson's 2 test with the statistical package SPSS version 7.5 for Windows (SPSS, Chicago, IL).
RESULTS
Patients and Samples
A total of 108 patients with advanced (AJCC stages III and IV 13 ) melanoma were enrolled, of whom nine were excluded (tissue DNA degradation). Among the remaining 99 patients, paired samples of primary melanomas (n ϭ 102; three patients had two primary tumors each) and synchronous or asynchronous metastases (n ϭ 165) were collected ( (Table 1 ). In the control melanoma cell lines, the equivalent rate of BRAF/NRAS mutations was 21 (72%) of 29, including a BRAF mutation frequency of 17 (59%) of 29 and NRAS mutation prevalence of four (14%) of 29 (Table 1) . In our series, no concomitant mutations of BRAF and NRAS genes were detected.
All but one of the BRAF mutations across samples was of the BRAF V600 subtype. Of these 135 mutations, 123 (91%) were BRAF V600E, occurring in 42% of all patient samples (39% of primary tumors and 44% of metastatic sites [range, 40% to 53%]). Likewise, 13 (45%) of the 29 control melanoma cell lines exhibited BRAF V600E (76% of the 17 BRAF V600 mutations). Other V600 subtypes identified were V600K, V600D, and V600R (Table 1) .
Among the 99 patients who had paired samples of primary and secondary melanomas, 84 (85%) showed consistent mutation patterns between primary tumors and metastatic lesions. In particular, the frequency of BRAF/NRAS mutations was highly consistent between the primary tumor and metastases in the lymph nodes and visceral sites. Of 84 patients with lymph node metastases, 78 (93%) had paired primary and secondary tumor samples that had the same BRAF/NRAS mutations. Similarly, for visceral metastases, 24 (96%) of 25 patients showed similar BRAF/NRAS mutation status between primary and secondary tumors (Table 2) . However, in patients with data available for brain and skin metastases, rates of consistency in BRAF/NRAS mutations between primary and secondary samples were significantly lower than for lymph and visceral metastases: 16 (80%) of 20 ( 2 P ϭ .0323) brain lesion samples and 27 (75%) of 36 ( 2 P Ͻ .001) skin secondary tumors exhibited the same BRAF/NRAS mutation status as the paired primary tumor (Table 2) .
Among the 20 paired samples (15 [15%] of 99 patients) with discrepancies in BRAF/NRAS mutation patterns between primary and secondary tumors, 10 (50%) displayed a wild-type primary tumor and a mutated metastasis (six in BRAF and four in NRAS), eight presented with a mutated primary tumor and a wild-type metastasis (seven in BRAF and one in NRAS), and two carried a change in mutation pattern between the two tumor lesions (an NRAS mutation in primary melanoma and a BRAF mutation in melanoma metastasis; Table 2 ). Overall, nine of the 20 discrepant metastatic lesions occurred in only four patients, whereas each of the remaining 11 patients carried a single discrepant metastatic lesion (Table 3) . Concordance in BRAF/NRAS mutation status among metastatic samples was then evaluated in the subset of 46 patients with paired multiple metastases (one lymph node and at least one other site lesion; Fig 1) . Rates of consistency in BRAF/NRAS mutations between lymph node and other site metastases were quite similar to those observed between primary and secondary tissues: 21 (91%) of 23 visceral lesions, five (83%) of six brain metastases, and 25 (76%) of 33 skin secondary tumors exhibited the same BRAF/NRAS mutation status as the paired lymph node sample (Appendix Table A2 , online only). The BRAF/NRAS mutation status was not evaluated for association with clinical outcome in our series.
p16CDKN2A Mutation Frequencies
Sixteen (16%) of the 99 patients had p16CDKN2A gene mutations. Among available DNA samples, the rate of mutations was much higher in melanoma metastases (21 [14%] of 151) versus primary melanomas (five [7%] of 74). The rate of consistency between secondary and primary tumor samples was five (31%) of 16. The highest prevalence of p16CDKN2A alterations was observed in our series of 29 melanoma control cell lines (62%; Table 4). Table 5 shows the distribution of mutations in the p16CDKN2A gene among the 16 patients identified as having this mutation, showing that in most of these patients (11; 69%) mutations existed only in metastatic sites, although the primary tumor exhibited wild-type status.
Finally, no correlation was inferred between p16CDKN2A and BRAF/NRAS mutations from either primary or secondary melanomas (Appendix Table A3 , online only). Regardless of p16CDKN2A mutation status, approximately 60% of samples had BRAF or NRAS mutations in both primary and metastatic sites.
DISCUSSION
Melanoma is a complex disease influenced by alterations in several genes and metabolic pathways that continue to evolve through the course of the disease. There is increasing evidence that melanoma develops as a result of accumulated genetic abnormalities within melanocytes. 17 The MAPK-ERK pathway, which includes the cascade of NRAS, BRAF, MEK1/2, and ERK1/2 proteins, is involved in the control of cell growth, proliferation, and migration. Mutations in this pathway may play a major role in the development and progression of melanoma. 5 In addition, the p16CDKN2A protein acts as a suppressor of cell proliferation, and dysfunction in this pathway is observed in many types of cancer. 18 In our study, we explored the relative frequency of genetic factors known to play a significant role in melanocyte development and their distribution among different melanoma tissues and disease progression sites.
As expected, a high prevalence of somatic mutations of BRAF and NRAS genes was detected in primary and secondary melanomas. The frequency of BRAF/NRAS mutations in primary tumors (43%/15%) was consistent with that reported in a meta-analysis in which BRAF mutation was present in 41% of cutaneous melanomas (n ϭ 2,521 patients) and NRAS mutation in 18% (n ϭ 1,972 19 Confirming previous data, 20 BRAF and NRAS mutations were mutually exclusive in our tissue sample collection. Overall, slightly higher rates of BRAF/NRAS mutation in metastatic (63%) versus primary site samples (58%) were observed in our series. A markedly higher rate of BRAF/NRAS mutations (72%) was detected in the control melanoma cell lines, mostly due to a higher BRAF mutation frequency (59% v 43% in primary tumors and 48% in metastatic sites). Since cultured melanomas are thought to represent cells with the most malignant phenotype, our observations support previous findings 21 in which selection of BRAF mutant alleles may occur during tumor progression. In this regard, the demonstration of a sequential increase in mutation rates for both BRAF and NRAS genes during melanoma progression-from in situ melanomas to the radial and vertical growth phases of invasive melanomas 22 -strongly suggests that BRAF/NRAS somatic mutations may not act as founder events in melanomagenesis.
Twenty paired samples from 15 patients (15%) demonstrated discrepancies in BRAF/NRAS mutation patterns between primary and secondary tumors, the highest frequency of these discrepancies being in patients with subcutaneous (25%; P Ͻ .001) or cerebral (20%; P ϭ .0323) metastases. In half the discrepant cases, we found a wildtype primary tumor and a mutated metastasis (60% BRAF and 40% NRAS). Again, this may represent a further indication that mutations in two such genes might be acquired and become prevalent during disease dissemination in a fraction of patients with melanoma. However, the most intriguing data were represented by the observation of wild-type metastases in cases with mutated primary tumors (nearly all in BRAF) or, to a lesser extent, a different mutation pattern between melanoma lesions (NRAS mutation in primary and BRAF mutation in secondary tumors) in the remaining half of the discrepant cases. These observations provide additional evidence that molecularly heterogeneous cell types may coexist in primary melanoma (presence of both BRAF-wild-type and BRAF-mutant as well as differently mutated tumor cells has indeed been described [21] [22] [23] ). However, it is still unclear ; both events may determine the proliferation arrest of BRAF/NRAS mutated cells. Alternatively, one could hypothesize that the mutated metastasis may derive from another unidentified primary melanoma (in a fraction of patients, no known primary tumor is indeed found among those with metastatic disease).
The BRAF V600E mutation was identified in 42% of tissue samples and 45% of control melanoma cell lines, consistent with the frequency observed in patients screened for inclusion in A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3), in which 47% of patients tested positive for the BRAF V600 variants following BRAF mutation analysis with the cobas-4800 BRAF-V600 Mutation Test. 26 Although it remains the most prevalent sequence variant reported in subsets of patients with melanoma, the incidence of the BRAF V600E mutation varies worldwide, from 23% in Chinese patients with melanoma 27 to 45% in Australian patients, 28 in which it appears to be associated with various clinical features such as an inverse association with cumulative sun exposure and a lower rate of tumor proliferation. In our series, other BRAF V600 mutation subtypes occurred in less than 10% of all samples (with V600K being the second most frequent variant); lower than the rate of 26% recently described by Long et al 29 in Australian patients. All known mutations at position V600 of BRAF result in constitutive activation of BRAF kinase, causing deregulated downstream signaling via MEK and ERK.
30-32
A more striking difference in the mutation frequency between primary melanoma, metastases, and cell lines was observed for p16CDKN2A (7%, 14%, and 28%, respectively). Inactivation by mutation of this gene seems to be selected during tumor progression; this is consistent with the finding that p16CDKN2A silencing promotes uncontrolled cell proliferation, tumor growth, and increased aggressiveness of tumor cells. 33, 34 Nevertheless, a functional relationship between p16CDKN2A inactivation and BRAF activation has been demonstrated. Oncogenic BRAF mutations constitutively induce upregulation of p16CDKN2A in melanocytic cells and, conversely, any genetic or epigenetic inactivation of p16CDKN2A may contribute to malignant progression of BRAF mutant cells.
24,33 Consistent with these findings, BRAF/NRAS and p16CDKN2A mutations were found to coexist (being detected at similar rates of around 60%) in our series of primary tumors and corresponding metastases.
Although p16CDKN2A remains a high penetrance melanoma susceptibility gene, oncogenic BRAF now represents an identifiable and proven target for cancer therapies. 35, 36 In melanoma, a phase III study of oral vemurafenib, a potent inhibitor of BRAF V600 mutations, demonstrated a relative reduction of 63% in the risk of death and 74% in the risk of either death or disease progression compared with dacarbazine chemotherapy in 675 patients carrying the BRAF V600E mutation. 26 Another inhibitor of mutated BRAF, GSK2118436 (GSK436), is under phase III evaluation in comparison with dacarbazine among BRAF-mutation-positive patients with stage III to IV melanoma (NCT01227889). A phase I/II study indicated a tumor response at 8 to 9 weeks in 60% of patients with metastatic melanoma or other solid tumors. 37 Despite evidence implicating NRAS in melanoma pathogenesis, 17 this gene has not yet become an effective target for melanoma treatment.
Together, these findings indicate that the future of melanoma therapy is likely to focus on targeting multiple pathways. However, the complexity of the molecular events underlying development and progression of melanoma suggests that a better comprehension of both the spectrum and distribution of alterations in molecular targets among patients with such a disease is crucial. In our study, we contributed to provide additional clues about the prevalence of BRAF/NRAS/p16CDKN2A mutations in synchronous or asynchronous paired tumor lesions from a large series of patients with melanoma. The observation of a high consistency between primary melanomas and lymph node or visceral metastases, in contrast with a significantly lower consistency between primary tumors and brain or skin metastases, may have implications in clinical practice. Starting from these findings, the prognostic value of such genetic alterations should be evaluated in a large cohort to assess whether the different distribution of BRAF/NRAS/ p16CDKN2A mutations in tumor lesions may have an impact on disease outcome among patients with melanoma. 
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